NASDAQ · Medical - Instruments & Supplies

HBIO (HBIO) Stock

$6.10 +0.16% NASDAQ: HBIO Healthcare

Valuation

MetricValue
Price$6.10
Market Cap$27.51M
P/E Ratio-0.42
P/B Ratio1.74
P/S Ratio0.28
EPS (TTM)$-12.80
52-Week High$9.40
52-Week Low$3.80
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-407.14%
ROA-71.25%
ROCE-7.14%
Gross Margin0.00%
Operating Margin-1.15%
Net Margin-11.44%
Debt/Equity4.39
Current Ratio2.18

Annual Financials (USD)

Metric20212022202320242025
Revenue$119.0M$113.0M$112.0M$94.0M$87.0M
Operating Profit$2.0M$-7.0M$2.0M$-6.0M$-1.0M
Net Profit$0$-10.0M$-3.0M$-12.0M$-57.0M
EPS$-0.07$-2.30$-0.80$-2.80$-12.80
Op Margin1.7%-6.1%1.7%-6.6%-0.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$162.0M$145.0M$137.0M$127.0M$80.0M
Total Liabilities$79.0M$73.0M$64.0M$63.0M$66.0M
Cash$8.0M$5.0M$4.0M$4.0M$9.0M
Borrowings$57.0M$54.0M$43.0M$44.0M$44.0M

Latest News

Sidoti Events, LLC's May Micro-Cap Virtual Conference ACCESS Newswire · May 20, 2026 Harvard Bioscience Inc (HBIO) Q1 2026 Earnings Call Highlights: Revenue Growth Driven by New ... GuruFocus.com · May 12, 2026 Harvard Bioscience, Inc. Q1 2026 Earnings Call Summary Moby · May 12, 2026 HBIO Q1 2026 Earnings Transcript Motley Fool · May 12, 2026 Harvard Bioscience: Q1 Earnings Snapshot Associated Press · May 12, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$1.0M$1.0M$14.0M$1.0M$7.0M
Investing Cash Flow$-3.0M$-3.0M$-4.0M$-5.0M$-3.0M
Financing Cash Flow$0$-1.0M$-2.0M$0$0
Net Cash Flow$0$-3.0M$0$0$5.0M
Free Cash Flow$0$0$12.0M$-2.0M$6.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA11.87
FCF Yield6.21%
Quick Ratio1.06
Interest Coverage-0.20
Return 1Y50.75%
Return 3Y-88.96%
Return 5Y-92.03%

Ownership

Insiders Held9.48%
Institutions Held41.46%
Institutions Float Held45.80%
Institutional HolderSharesReport Date
Weber Capital Management LLC /ADV320,0372026-03-31
Acadian Asset Management. LLC179,6142026-03-31
Vanguard Capital Management LLC163,3132026-03-31
Corsair Capital Management, L.P.124,8102026-03-31
Meros Investment Management, Lp118,5222026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CLGN $0.27 -9.04% -0.48 $3.54M 0.00%
COSM $0.21 +3.75% -0.44 $12.88M 0.00%
FEMY $3.06 -17.52% -0.74 $9.24M 0.00%
NCNANuCana plc $1.35 +3.05% -0.14 $8.20M 0.00%
NXGL $0.44 -0.57% 0.72 $4.03M 0.00%

About HBIO

HBIO is led by CEO John Duke, publicly traded since 2001.

HBIO stock trades at $6.10 with a market capitalization of $27.51M. The stock is valued at a price-to-earnings (P/E) ratio of -0.42, price-to-book of 1.74, price-to-sales of 0.28. Over the past 52 weeks the stock has ranged between $3.80 and $9.40, and currently trades 35.1% below its 52-week high.

On profitability, HBIO generates a return on equity (ROE) of -407.14%, return on capital employed of -7.14%, an operating margin of -1.15%, a net profit margin of -11.44%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides